



# Corporate Presentation

Bringing hope to people living with Neurodegenerative Diseases

This presentation has been prepared by Alpha Cognition Inc. (“ACI” or the “Company”). This presentation includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements include statements regarding the Company’s business strategy, future plans, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the technology. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements as a result of known and unknown risks, uncertainties, assumptions and other factors. These risks include those associated with clinical studies and manufacturing; risks around development and commercialization of the Company’s products; the need for additional financing to maintain operations; risks posed by the economic and political environments in which the Company operates and intends to operate; market instability due to the COVID-19 pandemic; the potential for losses arising from the expansion of operations into new markets; increased competition; assumptions regarding market trends and the expected demand and desires for the Company’s products and proposed products; reliance on industry manufacturers, suppliers and key personnel; the failure to adequately protect intellectual property; a failure to adequately manage future growth; adverse market conditions; and failure to satisfy ongoing regulatory requirements or obtain regulatory approvals. These forward-looking statements speak only as of the date of this presentation and, other than as required by applicable securities laws, the Company undertakes no obligation to revise or update any forward-looking statements, even if new information becomes available in the future.

This presentation also contains estimates and other statistical, market and industry data from independent parties or made by us relating to our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We cannot guarantee the accuracy and completeness of information from third party sources.

**ALL CURRENCIES DENOTED ARE IN UNITED STATES DOLLARS UNLESS OTHERWISE INDICATED**

# Leadership Has Impressive Track Record for Successful New Drug Development and Commercialization



**Michael McFadden**  
Chief Executive Officer



**Denis Kay**  
Chief Science Officer



**Lauren D'Angelo, MBA**  
Chief Commercial Officer



**Don Kalkofen**  
Chief Financial Officer

**UROVANT<sup>®</sup>**  
SCIENCES

**neurodyn**

**UROVANT<sup>®</sup>**  
SCIENCES

 **Protagonist**  
Therapeutics

 **AVANIR**  
pharmaceuticals

 **CNS|CRO**  
Preclinical Neurological Disease Services

 **AVANIR**  
pharmaceuticals

 **DEPOMED**

 **AMYLIN**

 **MEDIVATION**

**align**

**PHARMACIA**

**Genentech**

**Lilly**

**AstraZeneca** 

 **pwc**

# Alzheimer's Disease Overview

Alzheimer's (AD) is a type of dementia that causes a slow decline in memory, thinking and reasoning. Symptoms eventually grow severe enough to interfere with daily tasks and there is no cure.

## SIGNIFICANT MARKET

AD Impacts an estimated **6.3M** people in the U.S.<sup>1</sup>



Estimated to increase by to **7.2M patients by 2025**<sup>2</sup>



## UNMET MEDICAL NEED




**72% of Doctors** are **dissatisfied** with current treatments mainly due to **medication side effects (GI and insomnia)**




**55% of patients** **discontinue medication** therapy at 12 months, primarily due limited efficacy and side-effects<sup>4,5</sup>



# ALPHA-1062: A Potential Best-In-Class Treatment Designed To Minimize Side Effects



ALPHA-1062 bypasses active drug release in the GI tract, which minimizes GI side effects



ALPHA-1062 is metabolized in the liver, where galantamine is released



ALPHA-1062 may circulate with greater bioavailability (ability to be absorbed and used by the body). It modulates receptors responsible for inflammation, memory attention, and focus

**ALPHA-1062 was designed to work where it is supposed to (brain) and avoid activity in the gut (side effects)**

# Why Galantamine? Unique Brain Receptor Modulation and Excellent Long-Term Data

- Galantamine **affects multiple brain receptors to exert effect**
- Galantamine has **demonstrated anti-inflammation effects**<sup>2</sup>
- Galantamine has been associated with:<sup>3,5</sup>
  - **Improved Memory and Attention**
  - **Significantly lower risk of death** (P-value <0.001)
  - **Strongest ACHEI effect on cognitive decline**
- Use of Galantamine reduces **nursing home admission by 31% per year** of treatment<sup>4</sup>





# ALPHA-1062: Offers Potential Best-In-Class Profile

<b>Survival</b>	Galantamine, the active ingredient, demonstrated <b>lower risk of death</b>
<b>Long Term Outcomes<sup>1</sup></b>	<b>Significant risk reduction</b> in progression to severe dementia
<b>GI tolerability</b>	Active drug bypasses the gut, <b>lowering risk of GI</b> side effects
<b>CNS Profile</b>	<b>No insomnia</b>

*“...the hypothesis that disrupted sleep may exacerbate cognitive decline in AD has received significant support.”<sup>3</sup>*

*“...once the disease is present, sleep disturbances exacerbate the severity of the clinical picture.”<sup>4</sup>*



# Galantamine, the Active Moiety of ALPHA-1062, Demonstrates Strong Effect on Mortality and Cognitive Decline


- In an April 2021 *Neurology* publication, over **39,000 Alzheimer/Mixed Dementia patients** were evaluated with a 5 year average follow-up
- Galantamine demonstrated:
  - **Lower risk** of death
  - Strongest effect on **cognitive decline**
  - Significant **reduction in the risk** of developing severe dementia





# Studies Have Demonstrated Improved Gastrointestinal Side Effect Profile\*

~ 1% GI side-effects with oral formulations of ALPHA-1062  
(Delayed Release and Sublingual Tablets, n=148)



*\*Data from separate product monographs; comparative clinical significance has not been proven*

# US Public Markets Attribute Significant Value to AD

## UPON PH3 RESULTS, BIOGEN ADDED EQUIVALENT OF \$20B IN MARKET CAPITALIZATION

291.72 USD

+79.19 (37.26%) ↑ past year

Apr 18, 10:16 AM EDT • Disclaimer

1D | 5D | 1M | 6M | YTD | **1Y** | 5Y | Max



### PEER COMPANY

RESEARCH  
PHASE

MARKET  
CAP\*

ANNOVIS BIO, INC. (ANVS)

2

\$134M

ATHIRA PHARMA, INC. (ATHA)

2/3

\$104M

VIGIL NEUROSCIENCE, INC. (VIGL)

Preclin

\$355M

COGNITION THERAPEUTICS, INC.  
(CGTX)

2

\$51M

CASSAVA SCIENCES, INC. (SAVA)

3

\$1B

ANAVEX LIFE SCIENCES CORP. (AVXL)

3

\$638M

\*as of April 18, 2023; some products graphed are purported DMT vs ALPHA-1062 is a symptom treatment of disease

# Share Structure

ACOG.V, ACOGF		
Share Price (as of June 8, 2023)	\$0.245 CAD (\$0.18 US)	
Market Cap	\$23.3M CAD (\$17.5M US)	
June 8, 2023	Issued and Outstanding*	% of total
Common Shares	87,950,664	51.78%
Warrants	9,602,500	5.65%
Class A Restricted Shares	7,000,000	4.12%
Class B Preferred Series A Shares	7,916,380	4.66%
Performance Shares	8,471,057	4.99%
Non-Trading Warrants	27,833,700	16.39%
Stock Options	21,086,071	12.41%
TOTAL ALL SHARES	169,860,372	100%

\*PROFORMA

# Potential Catalysts and Upcoming Events

**2023**

- *Pre-IND meeting for ALPHA-1062 Intranasal in mTBI (Q2)*
- *TBI out-license to private company (Q3)*
- *NDA submission for ALPHA-1062 in AD (Q3)*
- *IND submission for ALPHA-1062 Intranasal for mTBI (Q4)*
- *Initiation of mTBI PH2 study (Q4) – contingent on TBI financing*

**2024**


- *Potential NASDAQ Listing*
- *ALPHA-1062 in AD product approval (Q3)*
- *ALPHA-1062 in AD commercial launch (Q4)*
- *ALPHA-1062 RESOLVE label expansion study initiation (Q4)*

**2025**

- *mTBI PH2 study results (Q1)*
- *ALPHA-1062 + Memantine pivotal trial initiation for Moderate to Severe AD (2H)*
- *ALPHA-1062 + Memantine pivotal trial results (2H)*
- *RESOLVE trial completion and sNDA submission (Q4)*



# Alpha Cognition Investment Thesis





**Don Kalkofen**  
**[info@alphacognition.com](mailto:info@alphacognition.com)**